2cureX – Presentation of the Year-End and Q4 2021 report
2cureX publishes its Year-End and Q4 2021 report on February 24th and on Tuesday March 1st at 14:00 HC Andersen Capital hosts a digital event where you can meet the CEO Fernando Andreu, Co-Founder & CSO Ole Thastrup and CFO Kenneth G. Johansen as they present the report.
2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.
The first two IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.
2cureX is currently implementing the first two IndiTreat® tests on the European market. 2cureX has established partnerships with IVD distributors in 14 countries covering a population of 235 million and 142,000 new colorectal cancer patients annually.
At the event, we expect the management to give an update on the roll-out plan and their commercial expectations for 2022. The event will be held in English.
*HC Andersen Capital receives payment from 2cureX for a Digital IR / Corporate Visibility subscription agreement.